21st Feb 2023 14:30
Spectral MD Holdings Ltd - Dallas, Texas-based predictive analytics company focused on algorithms and technology that allow for fast and more accurate treatment decisions - Begins a EU clinical study to support the development and regulatory submission of a diabetic foot ulcer application for its DeepView technology.
Company partners with the Royal College of Surgeons in Ireland's Skin Wounds & Trauma Research Centre to execute the study.
The intention of the clinical study is to further develop the DeepView AI-DFU algorithm and support the company's 2023 regulatory submissions for UK CA mark, the US Food & Drug Administration, and the EU CE mark.
Current stock price: 32.00 pence
12-month change: down 1.5%
By Heather Rydings, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2022 Alliance News Ltd. All Rights Reserved.
Related Shares:
SMD.L